ResultsIQ

ResultsIQ › Latest results › Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited Q1 FY27 results deck summary

NSE: AKUMS · BSE: 544222

Results deck of 8 Aug 2026, summarised by AI from the filing.

Q1 FY27 revenue ₹1,167 cr (+13.9% YoY) and PAT ₹101 cr (+56.1% YoY), led by CDMO volume growth; Oriflame India manufacturing acquired for ₹56 cr.

Key takeaways

  1. Q1 FY27 revenue Revenue ₹1,167 cr (Q1 FY26: ₹1,024 cr, +13.9% YoY), led by CDMO with double-digit volume growth.
  2. Guidance Management expects improved performance from domestic branded formulations and international branded formulations to return to growth.
  3. Oriflame acquisition On 23rd July, Akums announced the acquisition of Oriflame India's manufacturing business for ₹56 cr, adding two facilities.

Original filing on BSE

Akums Drugs and Pharmaceuticals Limited Q1 FY27 results

As filed: Revenue ₹1,167 cr (+14% year on year), EBITDA ₹175 cr (+35% year on year), PAT ₹101 cr (+55% year on year), EBITDA margin 15.0% (+238 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,158 cr (+10% year on year), EBITDA ₹152 cr (+61% year on year), PAT ₹81.3 cr (−46% year on year), EBITDA margin 13.1% (+420 bps). Score 49 of 100, In line with trend. EBITDA margin rose 420 bps year on year. Other income 29% of PBT. Not enough history for a trend yet: scored on growth alone. Share price after the results: +15.3% in 29 days (Nifty 500: +1.0%).
  • Q3 FY26: Revenue ₹1,160 cr (+15% year on year), EBITDA ₹147 cr (+21% year on year), PAT ₹67.7 cr (+37% year on year), EBITDA margin 12.7% (+68 bps). Score 53 of 100, In line with trend. EBITDA margin rose 68 bps year on year. Other income 34% of PBT. Consolidated profit +3% but standalone -31%. Not enough history for a trend yet: scored on growth alone. Share price after the results: +6.6% in 30 days (Nifty 500: −1.1%).
  • Q2 FY26: Revenue ₹1,018 cr (−1% year on year), EBITDA ₹95.0 cr (−22% year on year), PAT ₹43.0 cr (−36% year on year), EBITDA margin 9.3% (−248 bps). Score 7 of 100, Below trend. EBITDA margin fell 248 bps year on year. Other income 48% of PBT. Not enough history for a trend yet: scored on growth alone. Profit fell 34% from last quarter. Share price after the results: −3.3% in 29 days (Nifty 500: −0.4%).
  • Q1 FY26: Revenue ₹1,024 cr (0% year on year), EBITDA ₹129 cr (+2% year on year), PAT ₹65.0 cr (+7% year on year), EBITDA margin 12.6% (+13 bps). Score 28 of 100, Below trend. EBITDA margin rose 13 bps year on year. Other income 28% of PBT. Not enough history for a trend yet: scored on growth alone. Revenue fell 3% from last quarter. Share price after the results: −4.2% in 28 days (Nifty 500: +1.7%).
  • Q4 FY25: Revenue ₹1,056 cr, EBITDA ₹94.0 cr, PAT ₹150 cr, EBITDA margin 8.9%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,056 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −1.1% in 30 days (Nifty 500: +1.7%).
  • Q3 FY25: Revenue ₹1,010 cr, EBITDA ₹121 cr, PAT ₹66.0 cr, EBITDA margin 12.0%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,010 cr). Scored once a year-earlier consolidated quarter exists.
  • Q2 FY25: Revenue ₹1,033 cr, EBITDA ₹122 cr, PAT ₹67.0 cr, EBITDA margin 11.8%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,033 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Akums Drugs and Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.